elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33432473-27575063-2923-4451-B5D4-6ABF57974DD4
Q33432473-27575063-2923-4451-B5D4-6ABF57974DD4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33432473-27575063-2923-4451-B5D4-6ABF57974DD4
Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia.
P2860
Q33432473-27575063-2923-4451-B5D4-6ABF57974DD4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33432473-27575063-2923-4451-B5D4-6ABF57974DD4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4c1a20f1bcf34ee609f1db6973039c4364af2876
P2860
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.